Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMDTC in Participants With Solid Tumors Who Have Cisplatin-Induced Renal Insufficiency

NCT07824843 is registered in ClinicalTrials.gov with Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07824843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07824843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMDTC in Participants With Solid Tumors Who Have Cisplatin-Induced Renal Insufficiency
Lead sponsor
Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cisplatin adverse reaction, cisplatin nephrotoxicity